MATRIX: Advancing R&D Of Innovative HIV Prevention Products For Women

The Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence (MATRIX) is a USAID Project initiated in 2022 to Advance the Research and Development of Innovative HIV Prevention Products for Women.

MATRIX is implemented and co-led by Magee-Womens Research Institute and Foundation, USA, and Wits RHI. This project is to advance the research and development of innovative HIV prevention products for women. Prof Thesla Palanee–Phillips, the Wits RHI Director of Clinical Trials is the Deputy Director for the MATRIX project.

There are 18 partner organisations working together with product developers to inform and accelerate early R&D for new HIV prevention products. The goal is to develop a range of products that are acceptable, affordable, scalable, and deliverable to meet the needs of women at risk of HIV and other infectious diseases through equitable North-South partnerships and rigorous evaluation.

For more research information click here